Can this gene editing company develop a functional cure for HBV?
DDW Editor Reece Armstrong speaks to Cassie Gorsuch, Vice President, Gene Therapy, at Precision BioSciences about limitations in treating hepatitis B (HBV) and the company’s recent clinical trial application (CTA) approval in Moldova for its lead candidate PBGENE-HBV.
RA: What are the limitations of current standard-of-care treatments for HBV?
CG: There is a large unmet need in treating patients with chronic hepatitis B, as current therapeutic strategies do not target the root cause of the disease. Nucleos(t)ide analogue treatments require daily chronic administrations that may result in viral suppression by reducing circulating HBV DNA. Because these therapies do not eliminate HBV cccDNA or inactivate integrated disease and only target the downstream mechanisms, only 1-3% of patients today achieve a functional cure on the current standard of care treatment.
Our approach to chronic hepatitis B at Precision is unique in that we’re looking to eliminate the entire replicating viral genome – the factory that makes the hepatitis B virus, known as cccDNA, while also inactivating integrated disease. The way that PBGENE-HBV works is the ARCUS nuclease recognises the target site and then creates a cut. After being cut, the cccDNA gets eliminated.
RA: Why has it been so difficult to develop curative treatments for HBV?
CG: Developing a cure for HBV is challenging due to the virus’ ability to create a persistent reservoir in the liver, known as cccDNA, which continues producing immune suppressing HBV S-antigen even on nucleos(t)ide analogue therapy and viral production rebounds if nucleos(t)sie analogues are discontinued. Targeting cccDNA with sufficient precision to eliminate it without affecting surrounding liver cells is technically complex. Precision’s ARCUS gene-editing platform directly addresses this challenge by specifically targeting and cutting a highly conserved 22-base pair sequence in cccDNA and in the virus that becomes integrated in the liver, an approach not previously used in clinical trials for HBV.
RA: How encouraging is the Moldova CTA for future regulatory approvals for PBGENE-HBV?
CG: Receiving the Moldova CTA is a major milestone, marking the first regulatory approval for a gene-editing therapy specifically designed to target the root cause of HBV. This approval allows Precision to begin clinical trials, dosing patients, and collecting safety and efficacy data. It also sets the stage for additional regulatory filings in global markets and supports our plan for an IND in the United States in 2025. Additionally, due to our robust safety package in the pre-clinical data, we will not have to wait for clinical data from one market to start in another.
RA: Could you discuss why targeting the HBV viral genome could drive a functional cure for patients with chronic hepatitis B?
CG: To be considered a functional cure, a patient must have no detectable HBV S-antigen or HBV DNA after discontinuation of treatment for six months or longer. We believe targeting the HBV cccDNA for elimination will disrupt the virus’ ability to replicate within liver cells. By addressing the two sources of HBV S-antigen, eliminating cccDNA and inactivating integrated HBV DNA, PBGENE-HBV should also reduce detectable HBV S-antigen and could potentially allow patients to cease all treatment, which is the ultimate goal for a functional cure.
RA: Why has there been such a lack of research into the elimination of the root cause of HBV – the cccDNA?
CG: Research into cccDNA has been limited due to its persistence within liver cells and the technical challenges of targeting it specifically without affecting healthy tissue. Standard therapies do not target cccDNA, which remains in the liver and can reactivate. The only other treatment aiming for the cccDNA are epigenetic editors which only temporarily silence the cccDNA and do not eliminate the viral reservoir which could still lead to liver cancer. Since the root cause of disease remains in the hepatocyte, epigenetic editors may not produce lasting responses needed to achieve a functional cure. In contrast, Precision is addressing this issue with PBGENE-HBV, aiming to offer a true functional cure by eliminating cccDNA.
RA: How does this approval help Precision Biosciences transition into a clinical stage in vivo gene editing company?
CG: The Moldova CTA approval is a significant step that validates our technology and approach, enabling us to generate clinical data and showcase the real-world efficacy of our ARCUS platform in tackling chronic hepatitis B and potentially other diseases.
RA: How big is the global impact of HBV and what is the unmet need for patients living with HBV?
CG: Chronic hepatitis B affects over 300 million people globally, with significant risks of cirrhosis, liver failure, and liver cancer. Over the course of 10-years as many as 40% of chronic hepatitis B patients will develop hepatocellular carcinoma or cirrhosis of the liver. Existing treatments only suppress the virus but do not eliminate the persistent cccDNA, so there’s a high unmet need for therapies that can offer a functional cure. PBGENE-HBV aims to address this significant gap by providing a treatment designed to eliminate the virus’ replication source.
RA: Could you discuss your wider global regulatory strategy for PBGENE-HBV?
CG: Precision is pursuing a comprehensive regulatory strategy, beginning with the Moldova CTA approval and the regulatory applications pending approval in other regions. This global approach enables us to demonstrate PBGENE-HBV’s safety and efficacy across diverse populations. We plan to file an IND in the US, aligning with our strategy to enroll the clinical trial rapidly and deliver accessible treatment to chronic hepatitis B patients worldwide.
RA: Could your genome editing approach be used for other viral infections?
CG: Yes, Precision’s ARCUS platform is designed to allow for protein engineering enabling precise modifications to target sites of our choosing. Depending on the target, we have the potential to use ARCUS for other serious and difficult to treat viral infections, but that is not in scope for us today. Beyond our lead programme targeting chronic hepatitis B virus, we are actively exploring applications of ARCUS in other areas. Our PBGENE programme targeting mitochondrial disease aims to eliminate mutant mitochondrial DNA associated with the m.3243A>G mutation. Preclinical studies have demonstrated the potential of ARCUS nucleases to selectively target and reduce mutant mitochondrial DNA, offering a promising therapeutic approach for this condition.
From DDW Volume 26 – Issue 1, Winter 2024/25 Read the digital issue
Biography:
Cassie Gorsuch, PhD, is VP of Gene Therapy at Precision BioSciences, leading preclinical ARCUS nuclease evaluations for in vivo gene editing. As a gene therapy expert, she heads Discovery, serves on partnership steering committees, and previously worked in life sciences with VWR.
